For research use only. Not for therapeutic Use.
Gefurulimab（Cat No.:I042089）is an investigational monoclonal antibody designed to target the PD-1 (programmed cell death protein 1) receptor, an immune checkpoint involved in the suppression of T-cell activity. By blocking PD-1, gefurulimab aims to enhance the immune system’s ability to recognize and attack tumor cells, thus improving anti-tumor immune responses. It is being studied in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma, to assess its safety, efficacy, and potential as a monotherapy or in combination with other immunotherapies for cancer treatment.
| Catalog Number | I042089 |
| CAS Number | 2456407-94-4 |
| Purity | ≥95% |
